News & Updates

Getting a heterologous vaccine booster appears to confer a greater protection against COVID-19 than homologous booster, suggest data from a Singapore study.

Adding lenzilumab, a monoclonal antibody targeting GM-CSF, on top of standard supportive care significantly improves survival without the need of invasive mechanical ventilation at 28 days in patients hospitalized with COVID-19 compared with standard care alone, reveals the LIVE-AIR study.

E-cigarette use, whether current or previous, is prevalent among adolescents with asthma, according to the results of a meta-analysis.

Smoking cessation programmes led and administered by community pharmacists appear to be effective, leading to high quitting and abstinence rates, a recent study has found. In contrast, the PharmQuit intervention, a mobile cessation assistance app, does not seem to be significantly better than standard quitting services.

While the mRNA vaccines currently available on the market have gained regulatory nods* for use in children aged 5 or 6 years old**, Moderna’s mRNA-1273 vaccine is setting a “new low” by showing that two 25 μg doses of the vaccine induce a robust immune response in infants/children as young as 6 months to <6 years of age, according to the latest data from the KidCOVE study.

Among patients with interstitial lung disease, cough-specific quality of life (QOL) is independently associated with adverse outcomes, specifically respiratory hospitalization, death, and lung transplantation, as reported in a study.